Clinical Trials

49 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01446133 2026-05-22

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

120 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04661007 2026-05-18

J-MIND

72 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Other hematologic neoplasmPlasma cell

18 enrolled

Leukemia, Plasma Cell, Multiple Myeloma

NCT03104842 2026-05-15

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

246 enrolled

Multiple Myeloma

NCT01955499 2026-05-13

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

39 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02160015 2026-05-13

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03269669 2026-05-13

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Lymphoma, Follicular

NCT05497804 2026-05-13

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT06169215 2026-05-13

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

70 enrolled

Multiple Myeloma

NCT06504199 2026-05-13

ZGR

39 enrolled

Lymphoma, Mantle-Cell

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT03901963 2026-05-08

AURIGA

200 enrolled 12 charts

Multiple Myeloma

NCT04722146 2026-05-08

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04923893 2026-05-08

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05050097 2026-05-08

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT06577025 2026-05-08

aMMbition

43 enrolled

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

208 enrolled 5 charts

Multiple Myeloma

NCT03556332 2026-05-05

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

41 enrolled

Multiple Myeloma

NCT04542824 2026-05-05

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-05-05

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-05-05

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04712097 2026-05-05

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT04978584 2026-05-05

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05429268 2026-05-05

firmMIND

82 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-05-05

EPCORE DLBCL-3

111 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06112847 2026-05-05

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

29 enrolled

Lymphoma, Follicular

NCT02343042 2026-05-04

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT03319667 2026-05-04

IMROZ

475 enrolled 1 FDA

Multiple Myeloma

NCT00843882 2026-05-01

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Classical hematologyMyeloidOther hematologic neoplasm

247 enrolled 19 charts

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

226 enrolled 16 charts

Smoldering Multiple Myeloma

NCT01522976 2026-04-30

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

282 enrolled 11 charts

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04653246 2026-04-30

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

52 enrolled

Multiple Myeloma

NCT00114101 2026-04-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

460 enrolled 11 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

306 enrolled 12 charts

Multiple Myeloma

NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT04224493 2026-04-20

SYMPHONY-1

555 enrolled

Lymphoma, Follicular

NCT04404283 2026-04-20

ECHELON-3

239 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-04-17

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

70 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05317416 2026-04-16

MagnetisMM-7

854 enrolled

Hematologic Diseases, Multiple Myeloma

NCT02420860 2026-04-15

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

113 enrolled

Multiple Myeloma

NCT01711554 2026-04-13

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

27 enrolled

CNS

Neuroblastoma

NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04133636 2026-04-13

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT01054196 2026-04-08

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

52 enrolled 15 charts

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 1 FDA

Multiple Myeloma

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03993912 2026-04-07

IFM2017_03

294 enrolled

Multiple Myeloma

NCT04824092 2026-04-01

frontMIND

899 enrolled